A Phase I, double blind, randomised, placebo-controlled, dose-escalating study of the safety, tolerability, food effect and pharmacokinetics of single and repeat doses of FT011 administered orally to healthy volunteers and patients with diabetic nephropathy associated with Type 2 diabetes
100 Clinical Results associated with Fibrotech Therapeutics Pty Ltd.
0 Patents (Medical) associated with Fibrotech Therapeutics Pty Ltd.
100 Deals associated with Fibrotech Therapeutics Pty Ltd.
100 Translational Medicine associated with Fibrotech Therapeutics Pty Ltd.